INVA · Innoviva, Inc.

Innoviva’s Q1 2026 results reflect a bifurcated performance: core operational metrics showed modest top-line growth and stable profitability, while non-operational gains—specifically $191.2 million in net favorable fair value changes of equity and long-term investments—dominated net income. Royalty revenue declined 4% year-over-year to $55.2 million (net), consistent with the $58.6 million gross royalty figure cited in the press release and reflecting amortization of capitalized fees. Net product sales surged 37% to $41.4 million, led by strong U.S. performance ($34.2M, +29% YoY) across GIAPREZA®, XACDURO®, and XERAVA®—indicating continued commercial traction at IST. Income from operations declined 8% to $38.2 million, attributed to increased investment in commercial activities and business development. The $186.6 million net income was overwhelmingly driven by mark-to-market gains, particularly Armata Pharmaceuticals’ share price appreciation, which contributed $157.7 million of the $191.2 million total. Management emphasized resilience of the royalty portfolio, progress at IST—including FDA approval and upcoming launch of NUZOLVENCE®—and disciplined capital allocation, evidenced by $20.4 million in share repurchases under the $125 million program. With $603.1 million in cash and $773.3 million in strategic healthcare investments as of March 31, 2026, Innoviva maintains substantial financial flexibility to pursue accretive opportunities amid variable market conditions. No forward-looking guidance was disclosed in the filing or Exhibit 99.1.